Protein and peptide biomarkers in organ transplantation

Biomarkers in Medicine

Volumn 6, Issue 3, 2012, Pages 259-271

  Sigdel, Tara K ^a   Gao, Xiaoxiao ^a   Sarwal, Minnie M ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

acute rejection; biomarker; kidney; organ dysfunction; organ transplantation; peptidomic; personalized medicine; proteomic; solid organ transplantation; transplant injury

Indexed keywords

ALPHA 1 MICROGLOBULIN; APELIN; APOLIPOPROTEIN A1; BETA 2 MICROGLOBULIN; BETA3 INTEGRIN; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 7; C REACTIVE PROTEIN; CD30 ANTIGEN; CD31 ANTIGEN; CHROMOGRANIN A; CXCL9 CHEMOKINE; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HERMES ANTIGEN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 16; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PEPTIDE; PROTEIN; RANTES; TROPONIN T; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT DYSFUNCTION; HEART TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PEDIATRIC SURGERY; PROTEOMICS; REVIEW;

BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; HUMANS; ORGAN TRANSPLANTATION; PEDIATRICS; PEPTIDES; PROTEINS;

EID: 84862876021     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.29     Document Type: Review

References (105)

1. Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome. Nature 409(6822), 860-921 (2001).
2. Krug K, Nahnsen S, Macek B. Mass spectrometry at the interface of proteomics and genomics. Mol. Biosyst. 7(2), 284-291 (2011).
3. Yates JR 3rd. Mass spectrometry. From genomics to proteomics. Trends Genet. 16(1), 5-8 (2000).
4. Huttenhain R, Malmstrom J, Picotti P, Aebersold R. Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 13(5-6), 518-525 (2009).
5. Poste G. Bring on the biomarkers. Nature 469(7329), 156-157 (2011).
6. Perkins D, Verma M, Park KJ. Advances of genomic science and systems biology in renal transplantation: a review. Semin. Immunopathol. 33(2), 211-218 (2011).
7. Perco P, Oberbauer R. Integrative analysis of -omics data and histologic scoring in renal disease and transplantation: renal histogenomics. Semin. Nephrol. 30(5), 520-530 (2010).
8. Lechler RI, Sykes M, Thomson AW, Turka LA. Organ transplantation - how much of the promise has been realized? Nat. Med. 11(6), 605-613 (2005).
9. Auffray C, Chen Z, Hood L. Systems medicine: the future of medical genomics and healthcare. Genome Med. 1(1), 2 (2009).
10. Ispas CR, Crivat G, Andreescu S. Review: recent developments in enzyme-based biosensors for biomedical analysis. Analytical Letts (45), 168-186 (2012).
11. Sarwal MM, Sigdel TK, Salomon DR. Functional proteogenomics - embracing complexity. Semin. Immunol. 23(4), 235-251 (2011).
12. Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N. Engl. J. Med. 363(15), 1451-1462 (2010).
13. Hricik DE, Rodriguez V, Riley J et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am. J. Transplant. 3(7), 878-884 (2003).
14. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 82(5), 663-668 (2006).
15. Schaub S, Nickerson P, Rush D et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am. J. Transplant. 9(6), 1347-1353 (2009).
16. Schaub S, Wilkins JA, Antonovici M et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant. 5(4 Pt 1), 729-738 (2005).
17. Camara NO, Silva MS, Nishida S, Pereira AB, Pacheco-Silva A. Proximal tubular dysfunction is associated with chronic allograft nephropathy and decreased long-term renal-graft survival. Transplantation 78(2), 269-275 (2004).
18. Teppo AM, Honkanen E, Finne P, Tornroth T, Gronhagen-Riska C. Increased urinary excretion of alpha1-microglobulin at 6 months after transplantation is associated with urinary excretion of transforming growth factor-beta1 and indicates poor long-term renal outcome. Transplantation 78(5), 719-724 (2004).
19. Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Salmela KT. Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int. 79(1), 89-98 (2011).
20. Ling XB, Sigdel TK, Lau K et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J. Am. Soc. Nephrol. 21(4), 646-653 (2010).
21. Chen R, Sigdel TK, Li L et al. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions. PLoS Comput. Biol. 6(9), pii: e1000940 (2010).
22. Terasaki PI. A personal perspective: 100-year history of the humoral theory of transplantation. Transplantation 93(8), 751-756 (2012).
23. Li L, Wadia P, Chen R et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and antibodyome measures. Proc. Natl Acad. Sci. USA 106(11), 4148-4153 (2009).
24. Mattoon D, Michaud G, Merkel J, Schweitzer B. Biomarker discovery using protein microarray technology platforms: antibody-antigen complex profiling. Expert Rev. Proteomics 2(6), 879-889 (2005).
25. Aboseif SR, Franke EI, Nash SD et al. The adjustable continence therapy system for recurrent female stress urinary incontinence: 1-year results of the North America Clinical Study Group. J. Urol. 181(5), 2187-2191 (2009).
26. Dinavahi R, George A, Tretin A et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J. Am. Soc. Nephrol. 22(6), 1168-1178 (2011).
27. Sigdel TK, Li L, Tran TQ et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J. Am. Soc. Nephrol. 23(4), 750-763 (2012).
28. Regele H. Non-HLA antibodies in kidney allograft rejection: convincing concept in need of further evidence. Kidney Int. 79(6), 583-586 (2011).
29. Yasui H, Yoshimura N, Kobayashi Y et al. Microstructural changes of bile canaliculi in canine liver: the effect of cold ischemia-reperfusion in orthotopic liver transplantation. Transplant. Proc. 30(7), 3754-3757 (1998).
30. Chinese Human Liver Proteome Profiling Consortium. First insight into the human liver proteome from PROTEOME(SKY)-LIVER(Hu) 1.0, a publicly available database. J. Proteome Res. 9(1), 79-94 (2010).
31. Friedman BH, Wolf JH, Wang L et al. Serum cytokine profiles associated with early allograft dysfunction in patients undergoing liver transplantation. Liver Transpl. 18(2), 166-176 (2012).
32. Levitsky J, Salomon DR, Abecassis M et al. Clinical and plasma proteomic markers correlating with chronic kidney disease after liver transplantation. Am. J. Transplant. 11(9), 1972-1978 (2011).
33. Micheloud D, Salcedo M, Banares R et al. Serum levels of fibrosis biomarkers measured early after liver transplantation are associated with severe hepatitis C virus recurrence. Transpl Infect Dis.11(2), 183-188 (2009).
34. Emadali A, Muscatelli-Groux B, Delom F et al. Proteomic analysis of ischemia-reperfusion injury upon human liver transplantation reveals the protective role of IQGAP1. Mol. Cell. Proteomics 5(7), 1300-1313 (2006).
35. Avellini C, Baccarani U, Trevisan G et al. Redox proteomics and immunohistology to study molecular events during ischemia-reperfusion in human liver. Transplant Proc. 39(6), 1755-1760 (2007).
36. Vascotto C, Cesaratto L, D'ambrosio C et al. Proteomic analysis of liver tissues subjected to early ischemia/reperfusion injury during human orthotopic liver transplantation. Proteomics 6(11), 3455-3465 (2006).
37. Taylor DO, Stehlik J, Edwards LB et al. Registry of the International Society for Heart and Lung Transplantation: twenty-sixth official adult heart transplant report-2009. J. Heart Lung Transplant. 28(10), 1007-1022 (2009).
38. Mehra MR, Uber PA, Uber WE, Park MH, Scott RL. Anything but a biopsy: noninvasive monitoring for cardiac allograft rejection. Curr. Opin. Cardiol. 17(2), 131-136 (2002).
39. Dos Remedios CG, Liew CC, Allen PD, Winslow RL, Van Eyk JE, Dunn MJ. Genomics, proteomics and bioinformatics of human heart failure. J. Muscle Res. Cell. Motil. 24(4-6), 251-260 (2003).
40. Pascual-Figal DA, Garrido IP, Blanco R et al. Soluble ST2 is a marker for acute cardiac allograft rejection. Ann. Thorac. Surg. 92(6), 2118-2124 (2011).
41. Corbett JM, Why HJ, Wheeler CH et al. Cardiac protein abnormalities in dilated cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 19(11), 2031-2042 (1998).
42. Meirovich YF, Veinot JP, De Bold ML et al. Relationship between natriuretic peptides and inflammation: proteomic evidence obtained during acute cellular cardiac allograft rejection in humans. J. Heart Lung Transplant. 27(1), 31-37 (2008).
43. Valantine H. Cardiac allograft vasculopathy after heart transplantation: risk factors and management. J. Heart Lung Transplant. 23(5 Suppl.), S187-S193 (2004).
44. De Souza AI, Wait R, Mitchell AG, Banner NR, Dunn MJ, Rose ML. Heat shock protein 27 is associated with freedom from graft vasculopathy after human cardiac transplantation. Circ. Res. 97(2), 192-198 (2005).
45. Kienzl K, Sarg B, Golderer G et al. Proteomic profiling of acute cardiac allograft rejection. Transplantation 88(4), 553-560 (2009).
46. Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am. J. Respir. Crit. Care Med. 166(4), 440-444 (2002).
47. Nelsestuen GL, Martinez MB, Hertz MI, Savik K, Wendt CH. Proteomic identification of human neutrophil alpha-defensins in chronic lung allograft rejection. Proteomics 5(6), 1705-1713 (2005).
48. Zhang Y, Wroblewski M, Hertz MI, Wendt CH, Cervenka TM, Nelsestuen GL. Analysis of chronic lung transplant rejection by MALDI-TOF profiles of bronchoalveolar lavage fluid. Proteomics 6(3), 1001-1010 (2006).
49. Korfei M, Schmitt S, Ruppert C et al. Comparative proteomic analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and lung transplant donor lungs. J. Proteome Res. 10(5), 2185-2205 (2011).
50. Egidi FM. Management of hyperglycaemia after pancreas transplantation: are new immunosuppressants the answer? Drugs 65(2), 153-166 (2005).
51. Sutherland DE, Gruessner RW, Dunn DL et al. Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann. Surg. 233(4), 463-501 (2001).
52. Folli F, Guzzi V, Perego L et al. Proteomics reveals novel oxidative and glycolytic mechanisms in Type 1 diabetic patients' skin which are normalized by kidney-pancreas transplantation. PLoS ONE 5(3), e9923 (2010).
53. Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ. Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. J. Alzheimers Dis. 30(2), 323-236 (2012).
54. Sigdel TK, Lau K, Schilling J, Sarwal M. Optimizing protein recovery for urinary proteomics, a tool to monitor renal transplantation. Clin. Transplant. 22(5), 617-623 (2008).
55. Thongboonkerd V, Chutipongtanate S, Kanlaya R. Systematic evaluation of sample preparation methods for gel-based human urinary proteomics: quantity, quality, and variability. J. Proteome Res. 5(1), 183-191 (2006).
56. Khan A, Packer NH. Simple urinary sample preparation for proteomic analysis. J. Proteome Res. 5(10), 2824-2838 (2006).
57. Sigdel TK, Sarwal MM. The proteogenomic path towards biomarker discovery. Pediatr. Transplant. 12(7), 737-747 (2008).
58. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotech. 24(8), 971-983 (2006).
59. Grizzle WE, Bell WC, Sexton KC. Issues in collecting, processing and storing human tissues and associated information to support biomedical research. Cancer Biomark. 9(1-6), 531-549 (2011).
60. Rui Chen GIM, Li-Pook-Than J, Jiang L et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 148(6), 1293-1307 (2012).
61. Klein J, Jupp S, Moulos P et al. The KUPKB: a novel web application to access multiomics data on kidney disease. FASEB J. 26(5), 2145-2153 (2012).
62. Mandrekar SJ, Sargent DJ. Design of clinical trials for biomarker research in oncology. Clin. Investig.1(12 1629-1636 2011
63. Schilsky RL, Doroshow JH, Leblanc M, Conley BA. Development and use of integral assays in clinical trials. Clin. Cancer Res. 18(6), 1540-1546 (2012).
64. Ampatzidou F, Koutsogiannidis CP, Ananiadou O, Liosi M, Asteri T, Drossos G. Neutrophil gelatinase-associated lipocalin as emerging biomarker of acute renal failure in renal transplant patient after coronary artery bypass surgery. J. Cardiovasc. Surg. (2012) (Epub ahead of print).
65. Marquez E, Sadowski E, Reese S et al. Serum HSP27 is associated with medullary perfusion in kidney allografts. J. Nephrol. doi:10.5301/jn.5000099 (2012) (Epub ahead of print).
66. Dinavahi R, George A, Tretin A et al. Antibodies reactive to non-HLA antigens in transplant glomerulopathy. J. Am. Soc. Nephrol. 22(6), 1168-1178 (2011).
67. Ho J, Rush DN, Karpinski M et al. Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical tubulitis. Transplantation 92(8), 878-882 (2011).
68. Johnston O, Cassidy H, O'Connell S et al. Identification of beta2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods. Proteomics Clin. Appl. 5(7-8), 422-431 (2011).
69. Srivastava M, Eidelman O, Torosyan Y, Jozwik C, Mannon RB, Pollard HB. Elevated expression levels of ANXA11, integrins beta3 and alpha3, and TNF-alpha contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics Clin. Appl. 5(5-6), 311-321 (2011).
70. Xu X, Huang H, Cai M et al. Serum hematopoietic growth factors as diagnostic and prognostic markers of acute renal allograft rejection: a potential role for serum stem cell factor. Cytokine 56(3), 779-785 (2011).
71. Malyszko J, Przybylowski P, Malyszko J, Koc-Zorawska E, Mysliwiec M. Tumor necrosis factor-related apoptosis-inducing ligand is a marker of kidney function and inflammation in heart and kidney transplant recipients. Transplant Proc. 43(5), 1877-1880 (2011).
72. Nakorchevsky A, Hewel JA, Kurian SM et al. Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies. J. Am. Soc. Nephrol. 21(2), 362-373 (2010).
73. Sigdel TK, Kaushal A, Gritsenko M et al. Shotgun proteomics identifies proteins specific for acute renal transplant rejection. Proteomics Clin. Appl. 4(1), 32-47 (2010).
74. Niemann CU, Walia A, Waldman J et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl. 15(12), 1852-1860 (2009).
75. Kamali K, Abbasi MA, Farokhi B et al. Posttransplant soluble CD30 as a predictor of acute renal allograft rejection. Exp. Clin. Transplant. 7(4), 237-240 (2009).
76. Platt RE, Wu KS, Poole K, Newstead CG, Clark B. Soluble CD30 as a prognostic factor for outcome following renal transplantation. J. Clin. Pathol. 62(7), 662-663 (2009).
77. Delgado JC, Pavlov IY, Shihab FS. Post-transplant increased levels of serum sCD30 is a marker for prediction of kidney allograft loss in a 5-year prospective study. Transpl. Immunol. 22(1-2), 1-4 (2009).
78. Malyszko J, Malyszko JS, Mysliwiec M. Serum neutrophil gelatinase-associated lipocalin correlates with kidney function in renal allograft recipients. Clin. Transplant. 23(5), 681-686 (2009).
79. Di Grande A, Giuffrida C, Carpinteri G et al. Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. Eur. Rev. Med. Pharmacol. Sci. 13(3), 197-200 (2009).
80. Lebkowska U, Malyszko J, Lebkowska A et al. Neutrophil gelatinase-associated lipocalin and cystatin C could predict renal outcome in patients undergoing kidney allograft transplantation: a prospective study. Transplant Proc. 41(1), 154-157 (2009).
81. Malyszko J, Malyszko JS, Bachorzewska-Gajewska H, Poniatowski B, Dobrzycki S, Mysliwiec M. Neutrophil gelatinase-associated lipocalin is a new and sensitive marker of kidney function in chronic kidney disease patients and renal allograft recipients. Transplant Proc. 41(1), 158-161 (2009).
82. Costalonga EC, Melo NC, Rodrigues CE, Sette LH, Ianhez LE. The potential role of C-reactive protein in distinguishing cytomegalovirus from tuberculosis and bacterial infections in renal transplant recipients. Clin. Transplant. 23(5), 710-715 (2009).
83. Van Ree RM, De Vries AP, Oterdoom LH et al. Plasma procalcitonin is an independent predictor of graft failure late after renal transplantation. Transplantation 88(2), 279-287 (2009).
84. Ismail AM, Badawi RM, El-Agroudy AE, Mansour MA. Pretransplant detection of anti-endothelial cell antibodies could predict renal allograft outcome. Exp. Clin. Transplant. 7(2), 104-109 (2009).
85. Sutherland SM, Li L, Sigdel TK et al. Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int. 76(12), 1277-1283 (2009).
86. Connolly GM, Cunningham R, McNamee PT, Young IS, Maxwell AP. Troponin T is an independent predictor of mortality in renal transplant recipients. Nephrol. Dial. Transplant. 23(3), 1019-1025 (2008).
87. Peng W, Chen J, Jiang Y, Shou Z, Chen Y, Wang H. Acute renal allograft rejection is associated with increased levels of vascular endothelial growth factor in the urine. Nephrology 13(1), 73-79 (2008).
88. Jung DY, Park JB, Lee EN et al. Combined use of myeloid-related protein 8/14 and procalcitonin as diagnostic markers for acute allograft rejection in kidney transplantation recipients. Transpl. Immunol. 18(4), 338-343 (2008).
89. Malyszko J, Malyszko JS, Pawlak K, Wolczynski S, Mysliwiec M. Apelin, a novel adipocytokine, in relation to endothelial function and inflammation in kidney allograft recipients. Transplant Proc. 40(10), 3466-3469 (2008).
90. Peng W, Chen J, Jiang Y et al. Urinary fractalkine is a marker of acute rejection. Kidney Int. 74(11), 1454-1460 (2008).
91. Zou Y, Yang X, Jiang X et al. High levels of soluble Major Histocompatibility Complex class I related chain A (MICA) are associated with biliary cast syndrome after liver transplantation. Transpl. Immunol. 21(4), 210-214 (2009).
92. Coelho MC, Tannuri U, Tannuri AC, Reingenheim C, Troster EJ. Is procalcitonin useful to differentiate rejection from bacterial infection in the early post-operative period of liver transplantation in children? Pediatr. Transplant. 13(8), 1004-1006 (2009).
93. Zelzer S, Stiegler P, Kapitan M et al. Myeloperoxidase as serum marker for detection of CMV infections and rejections in patients after liver or heart transplantation. Transpl. Immunol. 20(3), 121-126 (2009).
94. Ilmakunnas M, Tukiainen EM, Rouhiainen A et al. High mobility group box 1 protein as a marker of hepatocellular injury in human liver transplantation. Liver Transpl. 14(10), 1517-1525 (2008).
95. O'Riordan A, Johnston O, Mcmorrow T et al. Identification of apolipoprotein AI as a serum biomarker of chronic kidney disease in liver transplant recipients, using proteomic techniques. Proteomics Clin. Appl. 2(9), 1338-1348 (2008).
96. Martinez-Dolz L, Almenar L, Reganon E et al. What is the best biomarker for diagnosis of rejection in heart transplantation? Clin. Transplant. 23(5), 672-680 (2009).
97. Kauke T, Kaczmarek I, Dick A et al. Anti-MICA antibodies are related to adverse outcome in heart transplant recipients. J. Heart Lung Transplant. 28(4), 305-311 (2009).
98. Crescioli C, Buonamano A, Scolletta S et al. Predictive role of pretransplant serum CXCL10 for cardiac acute rejection. Transplantation 87(2), 249-255 (2009).
99. Geiger M, Harake D, Halnon N, Alejos JC, Levi DS. Screening for rejection in symptomatic pediatric heart transplant recipients: the sensitivity of BNP. Pediatr. Transplant. 12(5), 563-569 (2008).
100. Kosanam H, Sato M, Batruch I et al. Differential proteomic analysis of bronchoalveolar lavage fluid from lung transplant patients with and without chronic graft dysfunction. Clin. Biochem. 45(3), 223-230 (2012).
101. Miyoshi K, Sano Y, Yamane M, Toyooka S, Oto T, Miyoshi S. Elevation of antidonor immunoglobulin M levels precedes acute lung transplant rejection. Ann Thorac Surg. 92(4), 1233-1238 (2011).
102. Meloni F, Giuliano S, Solari N et al. Indoleamine 2,3-dioxygenase in lung allograft tolerance. J. Heart Lung Transplant. 28(11), 1185-1192 (2009).
103. Vos R, Vanaudenaerde BM, De Vleeschauwer SI et al. C-reactive protein in bronchoalveolar lavage fluid is associated with markers of airway inflammation after lung transplantation. Transplant Proc. 41(8), 3409-3413 (2009).
104. Kawut SM, Okun J, Shimbo D et al. Soluble p-selectin and the risk of primary graft dysfunction after lung transplantation. Chest 136(1), 237-244 (2009).
105. Shah AS, Leffell MS, Lucas D, Zachary AA. Elevated pretransplantation soluble CD30 is associated with decreased early allograft function after human lung transplantation. Hum. Immunol. 70(2), 101-103 (2009).